Please login to the form below

Not currently logged in
Email:
Password:

BIAL

This page shows the latest BIAL news and features for those working in and with pharma, biotech and healthcare.

Neurocrine bags FDA approval for first tardive dyskinesia drug

Neurocrine bags FDA approval for first tardive dyskinesia drug

The company fleshed out its movement disorder pipeline earlier this year by licensing opicapone from Portuguese drug maker BIAL.

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Former Roche CEO joins BIAL board Former Roche CEO joins BIAL board

    He will now advised BIAL which has a strong presence in southern Europe and in Latin America and is looking to grow internationally. ... His incorporation is especially relevant to BIAL as it is a recognition of the work we have been developing.".

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics